SYNH - INCリサ―チ・ホ―ルディングス (Syneos Health Inc.) INCリサ―チ・ホ―ルディングス

 SYNHのチャート


 SYNHの企業情報

symbol SYNH
会社名 Syneos Health Inc (INCリサ―チ・ホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Commercial Physical_Biological Resarch  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 シネース・ヘルス(Syneos Health Inc.)(旧名:INC Research Holdings Inc.)はグローバル契約研究機関(CRO)である。同社はバイオ医薬品および医療機器業界のフェーズⅠからフェーズⅣ臨床開発サービスを主とする。同社は2つの事業セグメントを運営する。臨床開発サービス事業は、フルサービスのグローバル調査、並びに臨床モニタリング、調査者採用、患者募集、データ管理、顧客の医薬品開発プロセス、品質保証監査、専門的なコンサルティングサービスを支援するための調査報告書などの付帯サービスを含む一連の臨床開発サービスを提供する。フェーズⅠサービス事業は、フェーズⅠ試験の臨床開発サービスに重点を置く。フェーズⅠ試験には、科学的探索医学、概念実証段階によるヒト初回試験、確立された化合物におけるフェーズⅠ試験のサポートが含まれる。   INCリサ―チ・ホ―ルディングスは米国の開発業務受託機関(CRO)持株会社。バイオ医薬品及び医療デバイス業界の第一・第二臨床開発サ―ビスに重点を置く。中枢神経系、腫瘍学及びその他の複雑な疾患で、分化した治療アライメントや知識を顧客に提供。顧客のバイオ医薬品化合物、研究開発、投資、及び諸経費軽減の開発に注力したサ―ビスを提供。   inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.
本社所在地 3201 Beechleaf Court Suite 600 Raleigh NC 27604-1547 USA
代表者氏名
代表者役職名
電話番号
設立年月日 40391
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 21000人
url www.incresearch.com
nasdaq_url https://www.nasdaq.com/symbol/synh
adr_tso
EBITDA EBITDA ー
終値(lastsale) 47.545
時価総額(marketcap) 4892907251.055
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 SYNHのテクニカル分析


 SYNHのニュース

   FivepHusion team up with Treehill Partners and Syneos Health  2023/05/26 11:00:26 Seeking Alpha
FivepHusion has collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health (SYNH)…
   Veeva Systems: Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients  2023/05/24 11:06:00 Finanz Nachrichten
Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle BARCELONA, Spain, May 24, 2023 /PRNew…
   Life Line Screening Announces Kevin Vass as Chief Financial Officer  2023/05/18 17:30:00 Benzinga
Life Line Screening, the nation''s leading mobile preventive health screening company for cardiovascular disease and stroke risk, announces the expansion of its leadership team with Kevin Vass joining the organization as Chief Financial Officer. Mr. Vass comes with key experience from his time as Divisional Chief Financial Officer at Harman International, a Samsung company, Chief Financial Officer of StudyKIK, and most recently, Technology and Data Solutions Chief Financial Officer at Syneos Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005242/en/ Kevin Vass, CFO of Life Line Screening (Photo: Business Wire) "I am thrilled to be … Full story available on Benzinga.com
   Syneos Health Target Price Raised Amid $7.1B Acquisition News: Analyst Provides Insight  2023/05/16 18:34:55 Benzinga
Mizuho analyst Ann Hynes reiterated a Neutral rating on the shares of Syneos Health, Inc. (NASDAQ: SYNH ), raising the price target to $43 from $38 . The company recently announced a definitive agreement to be purchased by a group of private equity firms led by Elliott Investment Management for $7.1 billion, including the assumption of all debt. The price target has been raised, focusing on the pending acquisition deal. Also … Full story available on Benzinga.com
   Mizuho Securities maintains Syneos Health at ''buy'' with a price target of $43.00  2023/05/16 10:38:42 Investing.com
https://www.investing.com/news/pro/inc-research-holdings-inc-receives-investment-bank-analyst-rating-update-3083547
   FivepHusion team up with Treehill Partners and Syneos Health  2023/05/26 11:00:26 Seeking Alpha
FivepHusion has collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health (SYNH)…
   Veeva Systems: Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients  2023/05/24 11:06:00 Finanz Nachrichten
Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle BARCELONA, Spain, May 24, 2023 /PRNew…
   Life Line Screening Announces Kevin Vass as Chief Financial Officer  2023/05/18 17:30:00 Benzinga
Life Line Screening, the nation''s leading mobile preventive health screening company for cardiovascular disease and stroke risk, announces the expansion of its leadership team with Kevin Vass joining the organization as Chief Financial Officer. Mr. Vass comes with key experience from his time as Divisional Chief Financial Officer at Harman International, a Samsung company, Chief Financial Officer of StudyKIK, and most recently, Technology and Data Solutions Chief Financial Officer at Syneos Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005242/en/ Kevin Vass, CFO of Life Line Screening (Photo: Business Wire) "I am thrilled to be … Full story available on Benzinga.com
   Syneos Health Target Price Raised Amid $7.1B Acquisition News: Analyst Provides Insight  2023/05/16 18:34:55 Benzinga
Mizuho analyst Ann Hynes reiterated a Neutral rating on the shares of Syneos Health, Inc. (NASDAQ: SYNH ), raising the price target to $43 from $38 . The company recently announced a definitive agreement to be purchased by a group of private equity firms led by Elliott Investment Management for $7.1 billion, including the assumption of all debt. The price target has been raised, focusing on the pending acquisition deal. Also … Full story available on Benzinga.com
   Mizuho Securities maintains Syneos Health at ''buy'' with a price target of $43.00  2023/05/16 10:38:42 Investing.com
https://www.investing.com/news/pro/inc-research-holdings-inc-receives-investment-bank-analyst-rating-update-3083547
   FivepHusion team up with Treehill Partners and Syneos Health  2023/05/26 11:00:26 Seeking Alpha
FivepHusion has collaboration with Treehill Partners, a New York-based strategic and financial advisory firm specializing in healthcare industry transactions, and Syneos Health (SYNH)…
   Veeva Systems: Biopharma Leaders Connect at Veeva R&D and Quality Summit to Advance Innovation for the Industry and Patients  2023/05/24 11:06:00 Finanz Nachrichten
Bayer, Boehringer Ingelheim, GSK, LEO Pharma, Recordati, Syneos Health and more share learnings on driving efficiency across the product development lifecycle BARCELONA, Spain, May 24, 2023 /PRNew…
   Life Line Screening Announces Kevin Vass as Chief Financial Officer  2023/05/18 17:30:00 Benzinga
Life Line Screening, the nation''s leading mobile preventive health screening company for cardiovascular disease and stroke risk, announces the expansion of its leadership team with Kevin Vass joining the organization as Chief Financial Officer. Mr. Vass comes with key experience from his time as Divisional Chief Financial Officer at Harman International, a Samsung company, Chief Financial Officer of StudyKIK, and most recently, Technology and Data Solutions Chief Financial Officer at Syneos Health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230518005242/en/ Kevin Vass, CFO of Life Line Screening (Photo: Business Wire) "I am thrilled to be … Full story available on Benzinga.com
   Syneos Health Target Price Raised Amid $7.1B Acquisition News: Analyst Provides Insight  2023/05/16 18:34:55 Benzinga
Mizuho analyst Ann Hynes reiterated a Neutral rating on the shares of Syneos Health, Inc. (NASDAQ: SYNH ), raising the price target to $43 from $38 . The company recently announced a definitive agreement to be purchased by a group of private equity firms led by Elliott Investment Management for $7.1 billion, including the assumption of all debt. The price target has been raised, focusing on the pending acquisition deal. Also … Full story available on Benzinga.com
   Mizuho Securities maintains Syneos Health at ''buy'' with a price target of $43.00  2023/05/16 10:38:42 Investing.com
https://www.investing.com/news/pro/inc-research-holdings-inc-receives-investment-bank-analyst-rating-update-3083547

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 INCリサ―チ・ホ―ルディングス SYNH Syneos Health Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)